Skip to content

News

For more information, please contact us.

For more information, please contact us.

Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI

June 18, 2019

Read More

Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer

February 14, 2019

Read More

Atox Bio Announces Independent Safety Monitoring Committee Recommendation To Continue Phase 3 Study Of Reltecimod In Necrotizing Soft Tissue Infections

September 25, 2018

Read More

Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)

May 29, 2018

Read More

Atox Bio Closes $30 Million Investment

December 4, 2017

Read More

Atox Bio Awarded Next Milestone – based Option by BARDA to Support Continued Development of Reltecimod for Necrotizing Soft Tissue Infections

September 25, 2017

Read More

Atox Bio’s Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned

May 23, 2017

Read More

Atox Bio Announces Independent Safety Monitoring Committee Recommendation To Continue Phase 3 Study Of Reltecimod In Necrotizing Soft Tissue Infections

November 3, 2016

Read More

Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of Reltecimod for Necrotizing Soft Tissue Infections

June 15, 2016

Read More

Appetite suppressor? Atox flesh-eating bug phase III dials down immune reply

December 8, 2015

Read More

Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)

December 7, 2015

Read More

Atox Bio Announces Appointment of Biotech Veteran Daniel D. Burgess as Chairman of the Board

December 15, 2014

Read More

Atox Bio Awarded Contract worth up to $24 Million for the Development of Reltecimod by the Biomedical Advanced Research and Development Authority (BARDA)

September 29, 2014

Read More

Reltecimod granted orphan medicinal product designation in the European Union for the treatment of necrotizing soft tissue infections (NSTI)

August 4, 2014

Read More

Atox Bio Closes $23 Million Investment

July 24, 2014

Read More

Atox Bio Publishes Data Demonstrating the Broad Therapeutic Effect of its Flagship Product in Treating “Flesh Eating Bacteria”

April 10, 2013

Read More

Atox Bio Announces Positive Top Line Results in the Reltecimod Necrotizing Soft Tissue Infections (NSTI) Phase 2a Trial

November 20, 2012

Read More

FDA grants Fast Track designation to Atox Bio’s Reltecimod for the treatment of necrotizing soft tissue infections (NSTI)

September 10, 2012

Read More

Atox Bio Raises $3.25 million to Advance Development of Reltecimod, a Novel Therapy for the Treatment of Severe Bacterial Infections, Currently in Phase 2 Clinical Trials

December 20, 2011

Read More

Atox Bio granted orphan drug designation for Reltecimod for the treatment of necrotizing soft tissue infections (NSTI)

October 25, 2011

Read More

End of Phase 1-Atox Bio announces successful completion of phase 1 for Reltecimod, a novel immunomodulator being developed for severe bacterial infections and sepsis

May 12, 2011

Read More

Atox Bio raises $2.1 Million to advance development of Reltecimod, a novel therapy for the treatment of severe bacterial infections

October 14, 2010

Read More